Caribou Biosciences, Inc.
NASDAQ:CRBUBiotechnology
-$0.05 today
- Market cap
- $52.47M
- Beta
- 2.33
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.39
Volume 1.01M
Average 1.83M
CRBU Account Payables
Amounts the company owes suppliers for goods and services received.
Caribou Biosciences, Inc.NASDAQ: CRBU
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables falls 9.6% from a year ago
Account payables stood at $3.5M at the end of Q1 FY2026, down 9.6% from a year earlier and down 39.4% from the prior quarter. Over 3 fiscal years it compounded at +71.5% a year.
Context
- Account payables amounted to 2.4% of total assets at the end of Q1 FY2026, up 0.9 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -9.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 5.78M USD
- Year-over-year change
- +133.6%
- 4-year CAGR
- +9.7%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.78M | +133.6% |
| FY2024 | 2024-12-31 | 2.48M | -20.6% |
| FY2023 | 2023-12-31 | 3.12M | +172.3% |
| FY2022 | 2022-12-31 | 1.15M | -71.3% |
| FY2021 | 2021-12-31 | 3.99M | — |
Account Payables vs competitors
How CRBU compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -9.6% is the 7th highest of 11, against a peer median of -8.5%.
- Account payables amounts to 2.4% of total assets for CRBU, versus a peer median of 3.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | €26.01M EUR | -20.9% | +10.3% | 10.4% | |
| Mar 2026 | $6.31M USD | +13.5% | +15.4% | 6.3% | |
| Mar 2026 | $5.08M USD | -8.8% | +50.2% | 4.6% | |
| Mar 2026 | $4.99M USD | +75.3% | +15.3% | 7.8% | |
| Mar 2026 | $4.93M USD | -2.5% | -32.5% | 1.2% | |
| Mar 2026 | $4.49M USD | +75.8% | +100.0% | 4.6% | |
| Mar 2026 | $4.36M USD | -8.3% | -31.3% | 1.4% | |
| Mar 2026 | $3.5M USD | -9.6% | +71.5% | 2.4% | |
| Mar 2026 | $3.32M USD | -18.5% | -7.6% | 1.5% | |
| Mar 2026 | $2.07M USD | -64.5% | -16.2% | 1.7% | |
| Mar 2026 | $1.91M USD | -62.2% | -28.0% | 1.4% | |
| Peer median (excluding CRBU) | — | -8.5% | +1.4% | 3.1% | |
Competitors are the stored peer set for CRBU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 240.42M | 58.34M | 51.16M | 16.29M | 12.36M |
| Short-term Investments | 135.41M | 189.33M | 277.67M | 193.24M | 126.98M |
| Net Receivables | 8.12M | 4.66M | 3.86M | 3.25M | 2.98M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 671K | 1.12M | 1.22M | 1.78M | 2.91M |
| Total Current Assets | 391.19M | 260.25M | 338.84M | 219.38M | 145.23M |
| Property, Plant & Equipment (Net) | 4.89M | 34.91M | 40.45M | 39.29M | 24.43M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 45.3M | 77.07M | 51.33M | 49.13M | 3.55M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 975K | 1.54M | 1.59M | 5.52M | 2.15M |
| Total Non-current Assets | 51.16M | 113.52M | 93.37M | 93.94M | 30.14M |
| Total Assets | 442.36M | 373.77M | 432.21M | 313.31M | 175.37M |
| Account Payables | 3.99M | 1.15M | 3.12M | 2.48M | 5.78M |
| Short-term Debt | 259K | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 8.7M | 9.94M | 2.85M | 3.13M | 1.9M |
| Other Current Liabilities | 4.75M | 7.12M | 10.62M | 10.22M | 8.56M |
| Total Current Liabilities | 25.83M | 28.13M | 28.3M | 30.65M | 25.41M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 476K | 381K | 557K | 548K | 4.27M |
| Deferred Revenue (Non-current) | 22.03M | 15.95M | 6.1M | 3.32M | 1.75M |
| Other Non-current Liabilities | 6.19M | 1.65M | 2.94M | 785K | (4.27M) |
| Total Non-current Liabilities | 28.7M | 44.77M | 35.51M | 29.71M | 27.78M |
| Total Liabilities | 54.53M | 72.89M | 63.81M | 60.36M | 53.19M |
| Common Stock | 6K | 6K | 8K | 9K | 9K |
| Retained Earnings | (97.79M) | (197.22M) | (299.29M) | (448.39M) | (596.52M) |
| Accumulated OCI | (135K) | (1.52M) | 30K | 255K | 103K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 387.83M | 300.87M | 368.4M | 252.95M | 122.18M |
| Total Debt | 259K | 27.75M | 27.11M | 26.49M | 27.23M |
| Net Debt | (240.42M) | (30.59M) | (24.05M) | 10.19M | 14.87M |
Caribou Biosciences, Inc.
NASDAQ:CRBU
Intrinsic Alpha fair value
Locked
Current Price
$0.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.